Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF) is a leader in biofilm-disrupting technologies for advanced wound and scalp care. This page aggregates all official company announcements, providing stakeholders with timely updates on regulatory progress, product developments, and strategic initiatives.
Investors and industry professionals will find comprehensive coverage of FDA clearances, manufacturing partnerships, and global licensing agreements. Our curated news stream includes earnings reports, clinical advancements, and distribution expansions, ensuring you never miss critical developments affecting KNBIF's market position.
Key focus areas include updates about antimicrobial wound care solutions, scalp health innovations, and quality certifications like ISO 13485:2016. Bookmark this page for direct access to primary-source information about Kane Biotech's progress in combating biofilm-related health challenges worldwide.
Kane Biotech (OTC:KNBIF) reported third quarter 2025 results showing a sharp revenue decline to $8,499 from $1,282,698 year‑earlier as prior animal‑health manufacturing and a US distribution agreement terminated.
Third quarter gross loss was $(5,128) versus prior gross profit of $558,754; net loss was $(607,345). Cash on hand was $939,062. Operating expenses fell to $538,306 from $1,170,064, mainly from staff and compensation reductions.
Corporate progress: U.S. revyve case series exceeded enrollment targets (28 of a 25 target), strong clinical readouts (97% mean wound area reduction in 4 weeks; 100% diabetic wound closure <12 weeks in presented cases), a six‑log microbial reduction in burn preclinical data, and completion of a FDA 510(k) clearance submission for revyve Antimicrobial Wound Cleanser.
Kane Biotech (OTC:KNBIF) announced a non‑brokered private placement to issue up to 16 million common shares at $0.05 per share for gross proceeds of up to $800,000. Proceeds are intended for working capital and general corporate purposes. Certain insiders may participate. Closing is expected on or about December 17, 2025. All issued shares will be subject to a four‑month and one‑day hold period. The Offering is subject to necessary approvals, including the TSX Venture Exchange. Securities will not be registered in the United States and may not be offered or sold in the U.S. or to U.S. persons.
Kane Biotech (OTC:KNBIF) presented new clinical and preclinical data for its FDA‑cleared revyve Antimicrobial Wound Gel and revyve Wound Gel Spray at DFCon 2025 (Oct 23–25) and the Southern Region Burn Conference (Oct 30–Nov 2).
Key results: 97% average Percent Area Reduction (PAR) in 4 weeks for diabetic foot ulcers vs a 40–50% PAR benchmark; complete wound closure in 8–12 weeks across a multi‑center case series; preclinical burn data showing 99.99–99.9999% pathogen reduction within 30 minutes and antibiofilm activity sustained ≥7 days.
Kane Biotech (TSX-V:KNE) has submitted a 510(k) clearance application to the FDA for its revyve® Antimicrobial Wound Cleanser. This marks the company's third product in the revyve line, complementing their existing Antimicrobial Wound Gel and Gel Spray products.
The new cleanser is designed for routine wound management, specifically for irrigating acute and chronic wounds to reduce bacterial load and remove loose material. The product's formulation is based on the existing revyve Antimicrobial Wound Gel. Notably, the U.S. wound cleanser market exceeded $200M USD in 2024.
Kane Biotech (OTCQB:KNBIF) has successfully completed enrollment for its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing its target with 28 participants versus the planned 25. The studies, involving wound care and burn specialists in the U.S., focus on the FDA 510(k) cleared revyve Antimicrobial Wound Gel.
The company plans to present the clinical data at various medical meetings throughout 2025 and 2026. According to Interim CEO Dr. Robert Huizinga, there has been encouraging interest from both clinicians and patients, with revyve products showing potential to significantly improve outcomes for patients with challenging wounds and burns.
Kane Biotech (KNBIF) announced that Interim CEO Dr. Robert Huizinga will present clinical data for their FDA 510(k) cleared revyve® products at the Symposium on Advanced Wound Care Fall conference in Las Vegas.
Two significant case studies will be presented: The first demonstrates how revyve Antimicrobial Wound Gel successfully treated a two-year-old Stage 4 sacral ulcer, reducing pain scores from 10/10 to 0 and decreasing wound size over three weeks. The second case study shows how the gel, combined with vibrational debridement, achieved a 60% wound size reduction over eight weeks in a two-year-old venous leg ulcer, with pain scores dropping from 5/10 to 0.
Kane Biotech (TSX-V:KNE) reported challenging Q2 2025 financial results, with revenue declining to $27,997 from $620,437 in Q2 2024, primarily due to the sale of its animal health business. The company posted a net loss of $(348,541), improved from $(1,215,996) in the previous year.
Key developments include the election of three new directors to the board, termination of the ProgenaCare distribution agreement, and conversion of a $1 million insider loan into a convertible debenture. The company faces challenges with a PrairiesCan default notice for approximately $1.4 million outstanding.
Kane continues to advance its wound care initiatives, presenting preclinical data at major conferences and conducting clinical case studies for its revyve® portfolio, while seeking new US distribution partners.
Kane Biotech (KNBIF) presented significant preclinical data and clinical case studies for its revyve™ Antimicrobial Wound Gel at two major North American wound care conferences. The preclinical in vitro studies demonstrated remarkable protease inhibition, including 80% reduction in MMP activity, 82% reduction in elastase activity, and 100% reduction in collagenase and TACE enzyme activity.
Clinical case studies showed meaningful improvements in chronic wound patients, including wound size reduction, pain elimination, and improved tissue regranulation over 6-12 weeks. Notable cases included a 60% wound size reduction in a venous leg ulcer over two months and significant improvements in pressure wound cases.
Kane Biotech (TSX-V: KNE) has announced that Interim CEO Dr. Robert Huizinga will present at the 4th Advanced Wound Care Summit USA in Boston, MA from July 15-17, 2025. The summit brings together industry leaders, innovators, payers, and regulators in the wound care sector to discuss transforming breakthrough science into accessible therapies.
Dr. Huizinga's presentation will be made available on Kane's website on July 16, 2025.
FAQ
What is the current stock price of Kane Biotech (KNBIF)?
What is the market cap of Kane Biotech (KNBIF)?
